Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells
Thi H. O. Nguyen, Louise C. Rowntree, Lilith F. Allen, Brendon Y. Chua, Łukasz Kedzierski, Chhay Lim, Masa Lasica, Gayani S Tennakoon, Natalie R Saunders, Megan Crane, Lynette Chee, John F. Seymour, Mary Ann Anderson, Ashley Whitechurch, E. Bridie Clemens, Wuji Zhang, So Young Chang, Jennifer R. Habel, Xiaoxiao Jia, Hayley A. McQuilten, Anastasia A. Minervina, Mikhail V. Pogorelyy, Priyanka Chaurasia, Jan Petersen, Tejas Menon, Luca Hensen, Jessica A. Neil, Francesca L. Mordant, Hyon‐Xhi Tan, Aira F. Cabug, Adam K. Wheatley, Stephen J. Kent, Kanta Subbarao, Theo Karapanagiotidis, Han Huang, Lynn K. Vo, Natalie Cain, Suellen Nicholson, Florian Krammer, Grace Gibney, Fiona James, Janine M. Trevillyan, Jason A. Trubiano, Jeni Mitchell, Britt Christensen, Katherine Bond, Deborah A. Williamson, Jamie Rossjohn, Jeremy Chase Crawford, Paul G. Thomas, Karin A. Thursky, Monica A. Slavin, Constantine S. Tam, Benjamin W. Teh, Katherine Kedzierska
Abstract
T cells, together with their T cell receptor (TCR) repertoires, were robust in hematology patients, irrespective of B cell numbers, and comparable to healthy participants. Vaccinated patients with breakthrough infections developed higher antibody responses, while T cell responses were comparable to healthy groups. COVID-19 vaccination induces robust T cell immunity in hematology patients of varying diseases and treatments irrespective of B cell numbers and antibody response.